MTEX vs USNA
Mannatech Inc. and Usana Health Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | MTEX | USNA |
|---|---|---|
| Revenue | $108.0M | $925.3M |
| Net income | $-15.2M | $10.8M |
| Gross margin | 74.9% | 78.3% |
| Net margin | −14.1% | 1.2% |
| Return on equity | −897.3% | 2.0% |
| Diluted EPS | −$8.00 | $0.58 |
| Dividend / share | $0.20 | — |
| Payout ratio | 0.0% | — |
| Free cash flow | $-4.3M | $8.5M |
| Equity | $-5.2M | $533.1M |
| Net debt / equity | −0.97× | — |
| Current ratio | 1.10× | 2.24× |
| Revenue CAGR 5y | −6.5% | −4.0% |
| Profit CAGR 5y | — | −38.7% |
USNA bills 8.6× the revenue of MTEX, and MTEX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | MTEX | USNA |
|---|---|---|
| FY2025 | $108.0M | $925.3M |
| FY2024 | $117.9M | $854.5M |
| FY2023 | $132.0M | $921.0M |
| FY2022 | $137.2M | $998.6M |
| FY2021 | $159.8M | $1.2B |
| FY2020 | $151.4M | $1.1B |
| FY2019 | $157.7M | $1.1B |
| FY2018 | $173.6M | $1.2B |
| FY2017 | $176.7M | $1.0B |
| FY2016 | $180.3M | $1.0B |
Net income by year
Bottom line
| Fiscal year | MTEX | USNA |
|---|---|---|
| FY2025 | $-15.2M | $10.8M |
| FY2024 | $2.5M | $42.0M |
| FY2023 | $-2.2M | $63.8M |
| FY2022 | $-4.5M | $69.3M |
| FY2021 | $9.8M | $116.5M |
| FY2020 | $6.3M | $124.7M |
| FY2019 | $3.3M | $100.5M |
| FY2018 | $-3.9M | $126.2M |
| FY2017 | $-1.8M | $62.5M |
| FY2016 | $-586,000 | $100.0M |
Advertisement
AdSense · Rectangle 336×280
More in this industry